Navigation Links
CSC's DynPort Vaccine Company to Continue Plague Vaccine Development

FALLS CHURCH, Va., June 5 /PRNewswire/ -- CSC (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has been notified by the Department of Defense (DoD) that all future funding for advanced development of plague vaccine will be allocated to the existing DVC contract with the Joint Project Manager Chemical, Biological and Medical Systems' Joint Vaccine Acquisition Program (JVAP) Joint Product Management Office.

According to the decision, DVC will continue development of a recombinant plague vaccine candidate, rF1V, up to and including possible licensure by the U.S. Food and Drug Administration (FDA). The vaccine candidate is currently in Phase 2 clinical trials.

"We are pleased with the DoD's decision to move forward with development of rF1V," said Dr. Robert V. House, president of DVC. "This will allow us to focus our full energies on developing this crucial vaccine for protecting our nation's warfighters."

"We are very pleased that a decision has been made regarding a future plague vaccine for the DoD," said Richard Nidel, Deputy Joint Product Manager for the Joint Vaccine Acquisition Program.

Work will be performed by DVC at its headquarters in Frederick, Md., and at various subcontractor sites.

The rF1V plague vaccine candidate is designed to provide protection against the plague bacterium Yersinia pestis in aerosolized form. The vaccine was originally identified and developed by scientists working at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Their work involved the identification of suitable protein antigens and the development of the processes used to assess the performance of the vaccine. Further development and manufacture of the vaccine candidate has been achieved by DVC under the DoD JVAP contract. DVC has served as prime systems contractor for the JVAP since 1997.

The safety and efficacy of this product in humans has not been established. The product is currently under clinical investigation and has not been licensed by the FDA.

About JVAP

As part of the JPEO-CBD, JVAP's mission is to develop, produce, and stockpile FDA-licensed vaccine products to help protect the warfighter against biological warfare agents. JVAP consolidates the Department of Defense's efforts for the advanced development, testing, FDA licensing, production and storage of biological defense vaccines and other biologics.


The United States Army Medical Research Institute for Infectious Diseases (USAMRIID), located at Fort Detrick, Md., is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious diseases research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

About DVC

DynPort Vaccine Company LLC (DVC) manages product development programs and provides consulting, technical and program management services to U.S. government agencies and companies in the biotechnology and pharmaceutical industries. For more information, visit DVC is part of CSC's North American Public Sector business unit's Government Health Services Division. CSC's expertise in providing health services to government agencies has grown over the last five decades to offer commercial best practices integrated to meet federal, state and local healthcare requirements. Services range from optimizing claims processing to operating disease surveillance systems to vaccine development and management. CSC's ideas and solutions are improving the quality of health care with better information for better decisions to save lives and money.

About CSC

CSC is a leading information technology (IT) services company. CSC's mission is to be a global leader in providing technology-enabled business solutions and services.

With approximately 90,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC's own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in Falls Church, Va., CSC reported revenue of $16.5 billion for the 12 months ended March 28, 2008. For more information, visit the company's Web site at

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite vaccine, public should not get complacent about pneumococcal disease
2. Vaccine May Boost Survival of Brain Cancer Patients
3. Vaccine may double survival in patients with deadly brain tumors
4. New HIV browser gives researchers access to valuable data from vaccine trials
5. New vaccine approach prevents/reverses diabetes in lab study at Childrens Hospital of Pittsburgh
6. Jenny McCarthy & Jim Carrey Host the Historic Green Our Vaccines March and Rally in Washington DC on June 4, 2008
7. Study finds unique HIV vaccine formula elicits strong immune responses
8. AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
9. NIAID to advance B-cell approach to HIV vaccines
10. Vaccine triggers immune response, prevents Alzheimers
11. Prostate Cancer Vaccine Looks Promising in Early Trial
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: